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Abstract:
The global burden of diabetes mellitus (DM) is projected to keep escalating with a
burgeoning of the incidence and prevalence of cardiovascular disease sequalae, which are
its major cause of morbidity and mortality. Current antiplatelet therapies used for risk
factor reduction have limited efficacy, as such, further investigation into mechanisms
provoking platelet dysfunction is warranted. Cytosolic calcium (Ca2+) excess in DM
platelets is a well-documented phenomenon in the literature, and various mechanisms
have been postulated. However, the ramification of this observation on mitochondrial
health has not been explored. We hypothesize that the increase in cytosolic Ca2+ will be
absorbed by the mitochondria leading to free mitochondrial matrix Ca2+ surplus and
injury. Fluorescent calcium indicators were used to quantify the calcium stores in
platelets. Our data indicate that total and free mitochondrial matrix Ca2+ levels were
indeed elevated in DM platelets compared to healthy controls. Our findings suggest that
the overwhelming oxidative stress environment in DM results in tyrosine-nitration of
MICU1 (mitochondrial calcium uptake 1), an activator of MCU (mitochondrial calcium
uniporter). Additionally there is a 30% reduction in the negative MCU regulator, MICU2.
Combined, the excess entry of cytosolic calcium likely contributes to the observed
mitochondrial damage and dysfunction observed with DM platelets. Restoring platelet
calcium handling to homeostasis may alleviate platelet hyperactivity in DM.
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Introduction:
Epidemiology of Cardiovascular diseases in Diabetes Mellitus
Diabetes mellitus (DM) is a heterogeneous systemic disease characterized by a
lack of insulin (type 1 DM) or insulin insensitivity (type 2 DM) leading to high
circulating levels of glucose and dyslipidemia. The burden of DM has been steadily
increasing over the past decades with 9.4 % of the United States population currently
living with DM and an additional 33.9 % with impaired glucose tolerance (1).
Accelerated atherosclerosis resulting in microvascular and macrovascular complications
is prevalent amongst DM patients regardless of the underlying genetic or mechanistic
factors leading to type 1 and type 2 DM (2). There is a two to four-fold increase in risk
for cardiovascular disease (CVD) complications in DM and this risk rises by 11 – 16 %
for every 1 % increase in HbA1c (2, 3). The mortality rate is higher with a 60 % chance of
dying from cardiac disease compared to their non-diabetic counterparts (3). Populationbased studies in Denmark and Finland revealed no difference in age adjusted cox
proportional hazard ratios for cardiovascular death amongst DM patients without prior
myocardial infarction (MI) compared to non-diabetic patients with prior MI (4, 5),
providing evidence that diabetes is an independent risk factor for cardiovascular events.
DM leads to excessive thrombosis by stimulating the coagulation cascade,
inducing platelet hyperactivity, and instigating endothelial dysfunction. Platelet
dysfunction is an important pathophysiological contributor to the higher rates of
premature and recurrent thrombotic vascular events including coronary heart disease,
peripheral arterial disease (PAD), and strokes, observed in DM patients. Aggressive risk
factor management measures are the standard of care to curb the cardiovascular risk of

6
DM patients (6). These include glycemic control, lipid management, blood pressure
reduction, and administration of antiplatelet agents such as aspirin (ASA), which inhibits
cyclooxygenase-1 (COX-1) through acetylation reducing thromboxane synthesis, P2Y12
inhibitors like clopidogrel or GpIIbIIIa inhibitors e.g., abciximab. The current American
Diabetes Association (ADA) guidelines recommend the administration of low dose ASA
in patients with DM and a history of CVD as a secondary prevention strategy, and as a
primary prevention for DM patients with ASCVD risk >10% (6). Several trials have
shown that ASA has a clear role in the secondary prevention of ischemic events given the
27% odds reduction in major adverse cardiovascular events (MACE) in patients with a
prior history of a vascular event (2). However, its role in primary prevention is still
debated based on a nonsignificant 10% decrease in MACE in low risk patients (2).
Notwithstanding this benefit, DM patients are labeled a high-risk group where
ASA may have limited efficacy based on the metaanalysis conducted by the
antithrombotic trialist group that reported a 7% reduction in cardiovascular events in DM
as compared to a 25% reduction in non-DM patients (7). Additionally, studies have
shown that DM patients exhibit biochemical resistance to normal doses of clopidogrel (8,
9). Clopidogrel insensitivity was defined as absolute changes in platelet reactivity < 10%
after ADP induced platelet aggregation (8). A pilot study randomized 40 DM patients,
who had sub-optimal response to clopidogrel, to either a standard dose of 75 mg for 30
days or high dose of 150 mg for 30 days (9). Despite the enhanced platelet inhibition in
the high dose group, there was still residual platelet hyperactivity (9). Given the current
limitations of therapies available to address cardiovascular complications of diabetes, it is
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imperative to understand the underlying mechanisms contributing to aberrant platelet
function.

Platelet hyperactivity and increased thrombosis in DM
Platelets are anucleate discoid megakaryocyte derived cellular fragments with an
average size of 1.5 – 3 µm and lifespan of 8 – 10 days. The primary role of platelets is to
establish and maintain hemostasis upon vascular endothelial injury. Hyperactive platelets
play a role in CVD by microembolisation of the capillaries, local progression of vascular
lesions and triggering of acute arterial thrombosis (10). Most acute ischemic
cardiovascular and cerebrovascular events are precipitated by plaque disruption with
subsequent platelet adhesion, activation and aggregation forming an intravascular
thrombus.
Ultrastructural analysis of DM platelets reveals extensive budding of
microparticles as well as spreading and clumping, a marker of hyperactivation (11). DM
platelets are sensitive to sub-threshold stimuli due to increased expression of glycoprotein
receptors and adhesion molecules like CD36 and CD49b on their surface, and
translocation of activation markers such as P-selectin and CD63 from the α-granules to
the plasma membrane (12, 13). Furthermore, there is accelerated thrombopoiesis such
that the platelet population is younger and larger in size. These reticulated platelets
contain denser granules, secrete more serotonin and β-thromboglobulin, and produce
more thromboxane (TXA2) (14).
Chronic hyperglycemia alters platelet membrane structure through non-enzymatic
glycation of membrane proteins and lipids. Membrane lipid glycation has been postulated
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to alter expression of adhesion and activation receptors on platelets (10). Moreover, the
anchoring of these receptors in a phospholipid matrix of enhanced microviscosity
provides more exposure to the extracellular matrix and potential ligands (10). This leads
to reduced platelet membrane fluidity resulting in enhanced platelet adhesion. DM
patients have higher circulating levels of glycated low density lipoproteins (gly-LDL),
which are more resistant to classical LDL receptor clearance causing longer plasma halflife (15). Gly-LDL obtained from DM patient incubated with platelet rich plasma (PRP)
of normal subjects strongly stimulated thrombin-induced aggregation and TXA2
production (16). These factors contribute to heightened procoagulant activity in DM.
Platelet hyperactivation in DM is marked by an imbalance of prothrombotic and
antithrombotic factors in addition to intrinsic platelet dysfunction. A cross-sectional study
published in 1990 compared the urinary excretion of 11-dehydrothromboxane β2 amongst
participants with and without type II diabetes and observed that the excretion rate in DM
patients was more than 2 SDs above the normal mean (17). Furthermore, a strong
correlation has been described between thromboxane (TXA2) synthesis and
hyperglycemia (17). Intraplatelet glucose concentration parallels the extracellular
environment due to insulin-independent glucose entry (13). Intracellular hyperglycemia
activates the aldose reductase (AR)-dependent polyol pathway resulting in excess
reactive oxygen species (ROS) production that potentiates the PLCϒ2/PKC/p38αMAPK
signaling cascade providing more arachidonic acid substrates for TXA2 synthesis
contributing to exaggerated platelet activity (18). In the presence of epalrestat (an AR
inhibitor), collagen-activated platelets in hyperglycemic milieu released less TXA2 and
expressed less thromboxane receptor (TP) on their surface membrane (18).
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DM patients have reduced endothelial production of antithrombotic factors such
as prostacyclin (PGI2) and nitric oxide (NO). Stimulation of PGI2 receptors (IPR) on
platelets induces cAMP-dependent inhibition of platelet aggregation (19). PRP obtained
from both insulin dependent diabetics (IDDM) and non-insulin dependent diabetics
(NIDDM) required higher concentration of PGI2 to inhibit ADP-induced aggregation by
50 % (20, 21). Platelets from DM patients have decreased saturation of IPR by 3Hiloprost with a Bmax significantly lower than their healthy counterparts (19). This reduced
IPR occupancy was confirmed by western blot that revealed decreased expression of
combined glycosylated and non-glycosylated isoforms of IPR, which was inversely
correlated with HbA1c (19). This accounts for the decreased platelet sensitivity to PGI2.
Platelets express a constitutive form of nitric oxide synthase (NOS), which
synthesizes NO, a potent vasodilator and cGMP-dependent platelet aggregation inhibitor,
from L-arginine (13). Activity of platelet NOS is significantly reduced in DM patients
and is negatively correlated with the HbA1c (22, 23). In addition to the diminished basal
NOS activity in DM platelets, metabolic derangements further reduce NO levels. Excess
glucose diverted through the polyol pathway consumes NADP, which is a necessary
cofactor required for NO production (24). Chronic hyperglycemia begets surplus reactive
oxygen species, which also consume NO (24).
Insulin deficiency and resistance contribute to platelet dysfunction in DM.
Platelets express insulin receptors (IR) and insulin-like growth factor-1 (IGF-1) receptors
on their membrane surface (25). Insulin binding to its platelet receptors increases
expression of adenylate cyclase-linked prostacyclin receptor reducing platelet reactivity

10
(10). Insulin modulates endothelial production of PGI2 and NO. The metabolic
derangements in DM synergistically alter platelet structure, function and morphology.

Calcium Regulation in Diabetic Platelets
Calcium is an important secondary messenger orchestrating platelet activity
during primary hemostasis. Elevation in intracellular calcium concentration during
hemostasis is mediated by its release from compartments and influx across the plasma
membrane. The main intracellular stores of calcium in non-excitable cells like platelets
are the endoplasmic reticulum (ER), acidic organelles and mitochondria. Upon vascular
injury, platelets are exposed to and bind to sub-endothelial collagen through the
interaction of von-Willenbrand factor (vWF) with its Gp1b receptor initiating platelet
adhesion. This leads to the activation of phospholipase C (PLC) mediated hydrolysis of
membrane phospholipid, phosphatidylinositol 4,5-biphosphate (PIP2) to inositol 1,4,5triphosphate (IP3) and diacylglycerol (DAG). The release of calcium from the ER and
acidic organelles via activation of the IP3R by IP3 triggers flux from the extracellular
compartment through a process termed store operated calcium entry (SOCE) (26).
Stromal interaction molecule 1 (Stim1) is a type 1 transmembrane protein embedded in
the ER membrane with its intraluminal EF hands acting as an ER calcium sensor (26, 27).
Release of calcium from the ER disrupts calcium binding to Stim1 and thus, its
subsequent redistribution to activate plasma membrane protein, Orai1, which
multimerizes to form a channel, allowing calcium entry from the extracellular
compartment (26-28). Other routes of calcium movement include receptor-operated
channels (ROC) via purinergic receptor (P2X1) that undergoes a conformational change
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upon agonist binding allowing calcium flux and second-messenger operated calcium
entry (SMOCE) through DAG activation of TRPC6/TRPC3 on the platelet surface (26,
29). Elevation in cytosolic calcium leads to release of the contents of dense and alpha
granules, actin cytoskeleton reorganization resulting in shape change, membrane lipid
flipping to expose phosphatidylserine, membrane arachidonic acid metabolism to yield
thromboxane (TXA2) and inside out activation of the integrin, αIIbß3 (26). These sequence
of events mark the platelet activation phase in the primary hemostasis cascade.
Multiple studies have shown an increase in both basal cytoplasmic calcium
concentration and agonist-induced flux in DM patients compared to healthy controls (4,
(30). However, the consequences of elevated intracellular calcium on organelle and
global platelet function have not been defined.

Mitochondrial Dysfunction in Platelets
Mitochondria are the powerhouses of all cells. In addition to providing cellular
energy, mitochondria are involved in a wide variety of other cellular function and
responses including responding to cellular stressors, cellular differentiation, and cellular
metabolism. Calcium is integral to these processes providing real time regulation. For
example, calcium sensitive dehydrogenases such as isocitrate dehydrogenase, αketoglutarate dehydrogenase and pyruvate dehydrogenase influence bioenergetics. As
such careful regulation of calcium flux is necessary to maintain cellular balance and
health. Multiple studies have revealed that mitochondrial damage plays a role in platelet
dysfunction in DM (31, 32). However, the impact of mitochondrial calcium dysregulation
and overload on platelet dysfunction has not been characterized.
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Statement of Purpose:

Hypothesis
Chronic elevation of cytosolic calcium in diabetic platelets results in
mitochondrial redistribution and overload, which in turn causes mitochondrial and
ultimately platelet dysfunction.

Specific aims
i.

To measure endoplasmic reticulum, cytosolic and mitochondrial calcium
content in diabetic platelets.

ii.

To correlate changes in mitochondrial calcium content with platelet
dysfunction, particularly focusing on mitochondrial dysfunction and platelet
apoptosis.

iii.

To elucidate the mechanism for mitochondrial calcium overload in diabetic
platelets.
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Methods:
Platelet isolation
Venous blood was obtained from healthy controls and DM patients recruited to
the study at Yale School of Medicine (Yale IRB approved protocol HIC 1005006865).
HbA1c for DM subjects ranged from 6.7 to 11.9 and most subjects were on glucose
lowering therapies. Individuals selected as healthy controls were not taking any
medications and did not have any diseases known to interfere with platelet function. After
providing informed consent, participants were subjected to standard venipuncture
procedure and approximately 20 ml of blood was collected into tubes coated with 3.8%
trisodium citrate (w/v). Blood samples were processed with some modifications
according to the protocol described by Mustard et al (33). Whole blood was centrifuged
at 1200 rpm for 10 minutes. The PRP was collected and PGI2 at 1:1000 dilution and
apyrase were added. Platelets were sedimented from the PRP upon centrifugation at 2000
rpm for 10 minutes. The platelet poor plasma (PPP) was discarded. Platelets were washed
twice using platelet wash buffer (140 mM NaCl, 2.95 mM KCl, 1.07 mM MgCl2, 5 mM
NaHCO3, 10 mM HEPES, 500 µM NaH2PO4, 5 mM Glucose and 3 mg/ml BSA at pH
7.4) and then resuspended to a final concentration of 2 x 106 cells/ml.

Quantification of calcium stores
To quantify calcium content in different cellular compartments, platelets were
labeled with a variety of dyes.
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Cytosolic Calcium
For cytosolic calcium measurements, platelet suspensions were incubated with 5
µM Fluoforte (Kd = 389 nM; Enzo) and 0.02% pluronic acid (Sigma) for 30 minutes at
37°C followed by another 15 minutes incubation at room temperature. The suspension
was centrifuged at 2000 rpm for 10 minutes and the labeled platelets were resuspended in
platelet wash buffer. The fluorescence intensities were detected by flow cytometer
(LSRII). The excitation and emission wavelengths for fluoforte were 480/530 nm.
Platelets were gated based on characteristic side scatter (SSC) and forward scatter (FSC)
properties on flow cytometry.
Endoplasmic Reticulum Calcium Store
The basal fluorescence intensity of platelets labeled with Fluoforte was read using
the Synergy 2 microplate reader (BioTek) for 2 minutes. 1 µM thapsigargin (TG, a nonspecific inhibitor of the intracellular Ca2+ uptake pump SERCA) was added and
intensities obtained for another 2 minutes and then, the sample in a Ca2+ free buffer
containing 5 mM EGTA was incubated in the dark at room temperature for 30 minutes to
allow complete the depletion of the ER calcium content to the cytosol. After incubation,
the sample was read for 3 minutes until the plateau was reached. The Gen5 software
generated plots, which were further analyzed. The ER store was estimated as the change
in intensities with the addition of TG.
Mitochondrial Calcium
Washed platelets loaded with 5 µM Rhod2-AM (Kd = 570 nM; Abcam) and
0.02% pluronic acid were incubated for 15 minutes at 37°C and then in the presence of
100 µM MnCl2 for 30 minutes to quench the cytosolic calcium signal. The labeled
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platelets were washed once. Total mitochondrial calcium content was measured using
LSRII flow cytometer. To assess free mitochondrial calcium content, basal fluorescence
intensities were obtained for 2 minutes using a Synergy 2 microplate reader. Upon
addition of 10 µM carbonyl cyanide m-chlorophenyl hydrazone (CCCP) (Abcam) to
depolarize the membrane and release free mitochondrial matrix Ca2+, fluorescence
intensities were read for another 5 minutes until plateau was established. The excitation
and emission wavelengths for rhod2 were 550/580 nm.

Apoptotic Assay
Platelets were loaded sequentially with 20 nM Mitotracker Deep Red (Life
Technologies) for 30 minutes at 37°C. The mitotracker-loaded platelets were washed and
resuspended in 1X Annexin V buffer containing 1µM Annexin V for 15 minutes at room
temperature in the dark. Fluorescence intensities were measured using LSRII flow
cytometer. FACS plots generated grouped subpopulations of platelets into healthy,
activated and apoptotic fractions.

Electron Microscopy (EM)
Slides of human platelets were fixed with 2% glutaraldehyde and 2%
paraformaldehyde in 0.1 M sodium cacodylate (pH 7.4) for 2 hours at room temperature.
They were washed three times with 0.1 M cacodylate buffer at room temperature. Cells
were postfixed with 1% osmium tetroxide in 0.1 M cacodylate buffer for 1 hr at room
temperature. After rinsing with cold distilled water, tissue samples were dehydrated
slowly with ethanol and propylene oxide. The samples were embedded in Embed-812
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(EMS, USA) and were visualized using a scanning electron microscope (Yale Biological
EM Facility, New Haven, CT).

Co-immunoprecipitation
Three hundred microgram of total platelet lysates were cleared with protein A
magnetic beads (Biorad). The pre-cleared lysates were incubated with either MCU or
MICU1 antibodies at a dilution of 1:20 overnight at 4°C and rabbit IgG served as the
control. After incubation and washing, the immunoprecipitated samples were eluted with
1X SDS loading buffer for western blot analysis.

Western Blot
Thirty microgram of protein lysates were loaded into wells on a 12 % biorad gel.
Samples were subjected to SDS-PAGE at 100 V and transferred to a nitrocellulose
membrane at 80 V for 75 minutes. Membranes were blocked with 5% milk and probed
with the following antibodies: MCU, VDAC, MICU1, MICU2, Hexokinase 1 (HK1) and
β-actin. VDAC, MCU, MICU1, MICU2, HK1 and HK2 antibodies were obtained from
Cell Signaling. β -actin was obtained from Sigma. Images were obtained using image lab
and densitometry analysis performed with ImageJ software (NIH).

Data Analysis
All data were presented as mean ± standard error of the mean. Two-tailed t-test
determined statistical difference when two groups were compared and the level of
significance was set at p<0.05. Analysis of variance (ANOVA) followed by Tukey’s
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multiple comparism was performed for comparisons involving three groups. Statistical
analyses were performed using the Prism software (GraphPad Software, Inc, La Jolla,
CA).
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Results:
Characterization of intracellular calcium stores
The fluorescent calcium dyes, Fluoforte or Rhod2, targeted to either the cytosol or
mitochondria, were used to quantify the size of the calcium stores. The basal cytosolic
Ca2+ was 50 % higher in DM platelets compared to healthy controls (Figure 1a and b).
To measure the ER calcium load, the ER was depleted by the addition of thapsigargin, a
non-competitive inhibitor of the sarco/endoplasmic Ca2+ ATPase 2 (SERCA-2), to
fluoforte-loaded platelets. The rise in cytosolic calcium reflected the calcium store in the
ER. There was no significant difference in the ER Ca2+ between DM patients (2.962 ±
0.178) and healthy controls (3.3 ± 0.245) (Figure 1c and d).
Rhod2 AM has a net positive charge allowing it to sequester mainly in the
mitochondria. Remnant dye in the cytosol was quenched with the addition 100 µM
MnCl2 (Supplemental figure 1a). Manganese competes in a 1:1 fashion with calcium for
Rhod2 and quenches its emission fluorescence. Sequestration of the Rhod2 dye to the
mitochondria was confirmed via confocal microscopy based on its punctate distribution
after quenching (Supplemental figure 1b). The basal mitochondrial calcium content was
significantly higher in DM platelets as shown by raw fluorescence units obtained via flow
cytometry (Figure 2a and b). Addition of CCCP, a proton-uncoupling agent, led to a
robust release of free mitochondrial matrix Ca2+ from diabetic platelets (Figure 2c). Area
under curve calculations revealed that the total mitochondrial calcium content was almost
twofold higher in diabetic platelets (31.46 ± 1.697) than healthy controls (15.83 ± 1.179)
(Figure 2d).
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Correlation of mitochondrial calcium overload with mitochondrial dysfunction in
diabetic platelets
DM platelets were marked by profound mitochondrial damage indicated by the
loss of mitochondrial membrane potential (Figure 3a and c). In addition, the proportion
of platelets with phosphatidylserine (PS) exposure, which is a marker of platelet
procoagulant activity and apoptosis, was seven-fold higher in DM based on the annexin
V fluorescence (Figure 3a and b). Thus, the fraction of apoptotic platelets (59.37 ±
2.726 %) was substantially higher in DM samples compared to healthy subjects (16.46 ±
6.785 %) as represented by the FACS quadrant with the concomitant loss of
mitochondrial membrane potential and PS exposure (Figure 3a and d). Electron
microscopy images of diabetic and healthy platelets provide morphological evidence of
mitochondrial damage. The mitochondria in DM platelets were smaller and rounder with
breaks present in the inner and outer mitochondrial membrane (Figure 3e)
We sought to correlate mitochondrial calcium levels to the extent of platelet
dysfunction in DM by analyzing the various sub-populations, namely healthy (Q1),
activated (Q2) and apoptotic (Q3). Q1 comprised of platelets with intact mitochondrial
membrane potential and low PS exposure. Q2 was platelets with an intact mitochondrial
membrane potential and high PS exposure. Q3 included platelets with dissipated
mitochondrial membrane potential and high PS exposure. As diabetic platelets progressed
from healthy to activated states and eventually apoptotic states, there was a progressive
increase in the levels of mitochondrial calcium with the most significant difference being
between the Q1 and Q3 sub-sets (Figure 4).
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Mitochondrial Calcium Channel Expression in DM
Mitochondrial

calcium

uptake

is

energetically

favorable

due

to

the

electrochemical gradient established by the calcium concentration gradient and ΔΨm.
Hence, effective regulation of calcium entry is needed to prevent constitutive activation
of platelet death pathways and allow timely responses to the dynamic changes in
cytosolic calcium spiking for metabolism. To understand the process contributing to
mitochondrial calcium overload in DM, we assessed mitochondrial calcium channel
expression in DM platelets. The outer mitochondrial membrane is permeable and calcium
flux occurs with the aid of the voltage dependent anion channel (VDAC) and a
modulator, Hexokinase-1 (HK-1). The inner mitochondrial membrane (IMM) is
impermeable and the core channel, MCU along with its regulators, MICU1 and MICU2,
permit calcium entry. Flux across the IMM is the rate-limiting step for Ca2+ entry into
mitochondria. Western blot analysis revealed no change in expression of MCU, VDAC,
MICU1 and HK-1 but there was a 30% decrease in MICU2 protein levels (Figure 5).
Modified assembly of the MCU channel complex and post-translational
modifications resulting in conformational changes can affect fluxes of Ca2+ into the
mitochondria. Immunoprecipitation studies of MCU revealed no changes in the channel
composition in DM states. Under our experimental conditions, MICU2 was not
immunoprecpitated with MCU in both healthy and DM lysates.
Given the well-documented oxidative milieu in DM, oxidative modifications of
the channel complex were explored. Nitrotyrosine formation reflects the level of
peroxynitrite, an important marker of oxidative stress. Previous studies have reported that
the activities of various calcium channels namely SERCA and L-type channels are altered
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by tyrosine nitration due to chronic hyperglycemia and inflammation respectively (34,
35). We examined the expression of 3-nitrotyrosine (3-NT) by immunoprecipitating
MCU and probing with anti-3-NT antibody. The blot showed a distinct band around 47
kDa, which corresponds to MICU1 that was significantly abundant in the DM sample
(Figure 6a). The nitrosylation of MICU1 was confirmed by directly immunoprecipitating
MICU1 and blotting for 3-NT. The DM samples expressed more nitrosylated MICU1
(Figure 6b). The immunoprecipitation of more MICU1 for an equal amount of MCU in
DM suggests that 3-NT results in tighter MICU1-MCU contacts.
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Discussion:
Calcium is a crucial secondary signaling molecule that regulates a myriad of
processes integral to platelet activation in response to a stimulus. It has been known in
other cell types that mitochondria can control cytosolic calcium by their ability to
sequester and retain large amounts of this divalent cation. We demonstrated for the first
time to our knowledge that DM platelets contain higher total and free matrix calcium
levels indicating the mitochondria serve as sinks for cytosolic calcium excess and this
process is amplified by oxidative changes of channel components.
An assortment of mitochondrial activities is essential to normal platelet
physiology. Upon activation, platelets need to upregulate metabolism to meet the
subsequent cellular demand for aggregation. As such, there is an increased flux of
glucose into platelets after α–granule release of GLUT3 to the surface resulting in
increased aerobic glycolysis and ATP production (36). The timely induction of ATP
production requires the stimulation of TCA dehydrogenases by mitochondrial calcium.
Besides its role in energy provision, a few studies have characterized a direct
involvement of mitochondrial calcium in platelet procoagulant activity. PS exposure
enhances clot formation by providing a catalytic surface for the assembly of tenase and
prothrombinase complexes for fibrin formation (29). Simultaneous measurements of
calcium fluxes, ROS and ΔΨm in activated platelets revealed the sequential events that
contribute to PS exposure (37). Sustained elevations in cytosolic calcium transients were
temporally followed by mitochondrial calcium increases, which triggered mitochondrial
permeability transition pore (mPTP) opening in PS+ platelets (37, 38). Conditions that
inhibited mitochondrial calcium uptake such mitochondrial membrane depolarization
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with an ionophore abrogated PS exposure (37). The utility mitochondrial calcium under
physiological conditions underscores the importance of its regulation and maintenance of
homeostasis.
The initial event that perturbs mitochondrial calcium equilibrium in DM platelets
is an elevation in cytosolic calcium. This study corroborates previous findings of
increased basal cytoplasmic calcium in DM platelets. In addition, we report no difference
in the ER calcium store between DM patients and healthy controls. This implies that
abnormalities contributing to raised cytoplasmic calcium levels are related to dysfunction
of channels involved in removal of Ca2+ from the cytosol and flux across the plasma
membrane upon agonist binding. Na+/Ca2+ exchanger is a bidirectional calcium
transporter localized to the plasma membrane that is driven by the size of Na+ gradient,
Ca2+ gradient and membrane potential (30). In physiological conditions, it operates in the
forward direction extruding calcium into the extracellular environment (30). DM platelets
exhibit reduced Na+/K+ ATPase activity leading to increased cytosolic Na+ concentration
(39). In hyperglycemic states, elevated cytoplasmic Na+ provides the driving force for
Na+/Ca2+ exchanger to work in the reverse mode (30). Also, reduced activity of both
plasma membrane Ca2+ ATPase and SERCA-2 involved in extrusion of cytosolic Ca2+
contribute to calcium excess in DM platelets (34, 40).
Another mechanism involved in altered calcium mobilization is enhanced SOCE.
Hyperglycemia leads to increased activity of pp60src, a tyrosine kinase that
phosphorylates Stim1 upon ER calcium depletion (41). This exaggerated phosphorylation
in DM leads to robust Stim1-Orai associations facilitating calcium entry from the
extracellular medium (41). Hyperglycemia also causes a time and dose dependent
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translocation of TRPC6 channel to the platelet surface through activation of the
phosphatidylinositol 3-kinase pathway (42). Steady state calcium concentration is
dependent on the balance between influx and efflux mechanisms. The overexpression and
activation of import channels along with reduced clearance mechanisms portend DM
platelets towards cytosolic calcium retention.
The IMS calcium concentration reflects the cytosolic calcium milieu. MICU1 and
MICU2 localized to the intermembrane space (IMS) are critical regulators of MCU
activity contributing to the sigmoidal mitochondrial calcium response (43, 44). They both
have a pair of EF-calcium binding motifs for calcium sensing (43). These paralogs can
exist as heterodimers or homodimers (47). The affinity of MICU1 for Ca2+ is
approximately 15–20 µM and MCU is a Ca2+-selective channel with low affinity for Ca2+
suggesting that MICU1 plays a major role as an activator in response to a high cytosolic
Ca2+ concentration (45). Under resting cytosolic calcium concentrations (~100 nM),
MICU2 constitutively suppresses mitochondrial calcium import by MCU (46). The initial
rise of basal cytosolic calcium in DM platelets results in a higher fraction of MICU2 with
EF-hand bound to Ca2+ releasing its inhibitory effect on MCU resulting in increased
uptake perhaps to initially enhance energy metabolism. Eventually the prolonged basal
cytosolic Ca2+ excess in DM leads to a decrease in MICU2 expression that shifts the
MICU

interactions

from

MICU1-MICU2

heterodimerization

to

MICU1

homodimerization, which has a higher affinity for calcium uptake. These initial responses
to restore cytosolic calcium balance initiate mitochondrial matrix overload.
There is a synergistic relationship between Ca2+ signaling and ROS/RNS
generation. The overdrive of the electron transport chain (ETC) by hyperglycemia and
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rise in mitochondria calcium results in oxidative stress, which is a hallmark of diabetes.
Diabetic platelets undergo increased production of ROS, and resultant lipid and protein
modifications such as aldehyde, carbonyl adducts due to this chronic exposure to
hyperglycemia (7, 8). The abundance of superoxide anion (O2-) detected in DM platelets
reacts with platelet and endothelial derived NO to form peroxynitrite (ONOO-), a highly
reactive and unstable molecule. Peroxynitrite-derived free radicals are capable of
modifying proteins by forming oxidative adducts or nitration of tyrosine residues (47).
The overwhelming oxidative environment in DM platelets generates plenty
peroxynitrite radicals, that reacts with MICU1 given its proximity to the ETC in the
IMM. The activity of peroxynitrite radicals is limited by diffusion. The physicochemical
properties of tyrosine make its nitration have important biochemical consequences.
Tyrosine is composed of a large phenolic amphipathic side-chain that can interact with
water and participate in hydrogen bond formation, and undergo cation-π and non-polar
interactions (48). Addition of a nitro group to position C3 leads to decrease in the pKa of
the amino acid from 10 to 7 (48). These structural changes together with the bulkiness of
the nitro group, which imparts steric restrictions, will significantly affect the
conformation

of

MICU1

contributing

to

augmented

MCU

activity.

The

immunoprecipitation of more nitrosylated MICU1 for an equal amount of MCU in DM
platelets indicates that this oxidative modification results in a tighter MICU1-MCU
interaction. In summary, DM leads to cytosolic Ca2+ excess, which abates the inhibitory
effect of MICU2 via calcium binding and decreased expression as an initial
compensatory mechanism to restore cytosolic Ca2+ balance. The resulting mitochondrial
calcium rise spurs ROS and peroxynitrite production that nitrosylates MICU1 amplifying
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MCU calcium uptake. This dysregulated mitochondrial calcium influx begets a vicious
cycle with ROS production and progressive tyrosine nitration culminating in organelle
harm.
What are the consequences of mitochondrial calcium overload in DM platelets?
Blood glucose levels correlates with intraplatelet glucose concentration given the insulinindependent activity of GLUT3. In hyperglycemic states, platelets synthesize more acetyl
CoA due to amplified pyruvate dehydrogenase, a calcium sensitive rate-limiting enzyme,
and ATP citrate lyase activities (49). This results in increased ATP formation. However,
prolonged hyperglycemia in DM results in uncoupling of ETC yielding a decrease in
mitochondrial generation of ATP and enhanced ROS production.
Furthermore, platelet mitochondria are involved in executing cell death.
Apoptosis is a programmed cell death phenomenon that can be intrinsically or
extrinsically regulated. MPTP opening is also a critical event of mitochondria provoked
apoptosis responsible for the collapse of Ψm, permeabilization of inner and outer
mitochondrial membrane, and eventual release of proapoptotic proteins such as
cytochrome C into the cytosol (50). Although it is still debatable, the mPTP comprises of
cyclophilin D (Cyp D) in the matrix, adenine nucleotide translocactor (ANT) in the inner
mitochondrial membrane, and VDAC localized to the outer mitochondrial membrane
(50). Cyp D is the most validated component of the complex. As a regulator of the mPTP,
it is sensitive to calcium, which induces a conformational change in the protein allowing
it to bind to ANT and as such, higher matrix calcium levels become a permissive
activator of the mPTP (50). Treatment of normal platelet with cyclosporine A (CsA), an
inhibitor of the mPTP that affects Cyp D function, prevents mPTP formation and
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downstream events such as loss of ΔΨm and externalization of PS (51). MPTP opening
has been shown to occur substantially in DM platelets (52). In this study, DM platelets
exhibited marked externalization of PS, strong ΔΨm depolarization and extensive
apoptosis. Our observation of a gradual rise in mitochondrial calcium from healthy to
activated and apoptotic platelet fractions substantiates its role in DM platelet
pathophysiology.
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Clinical Vignette – Low Mitochondrial Calcium:
Chief Concern
69 year-old male with a history of multiple bleeding episodes and a recent stroke.
He was thought to have an aspirin-like platelet defect.
History of Presenting Illness:
His first bleeding episode occurred in 1991 when he had a nasal septal repair that
was complicated by a large amount of bleeding resulting in a hemoglobin drop from 15 to
9, necessitating use of plasma expanders in order to avoid blood product transfusions.
There was no surgical explanation for this amount of bleeding. Laboratory studies
performed showed normal platelet count and coagulation studies. However, platelet
aggregation tests showed no response to arachidonic acid and epinephrine (Table 1). In
addition, the patient had normal levels of thromboxane B2 (202 ng/ml) and serotonin
(173 ng/ml). Multiple aggregation studies were performed since the initial bleeding
incident and reached a similar conclusion (Table 1). Other tests evaluating different steps
of the coagulation cascade were within normal limits. The patient denied the use of any
aspirin or NSAIDs at the time of these tests.
Collagen 95 mcg/ml
1:2
1:3
ADP 2 mcM
Epinephrine 5 mcM
10 mCM
Ristocetin 1.25 mg/ml
0.31 mg/ml
Sodium Arachidonate 250
mcg/ml

1991
88 %
75 %
70 %
63 %
0%
7.5 %
88 %
0%
0%

1992
37.5 %
100 %
30 %
32.5 %
100 %
0%

2012
35 %

19 %
15 %
91 %
4%
1%

Table 1: Clinical platelet aggregation tests. Normal response is greater than 50%.
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History was also notable for excessive bleeding with minor injuries such as cuts
or bruises, and two hospitalizations for lower gastrointestinal bleeding attributed to
diverticulosis, requiring about 10 units of pRBCs. Labs revealed normal vitamin B12 and
folate levels, low ESR, normal C3 and C4 complement levels, and negative ANA.
In 12/2016, he developed dizziness and ataxia, which led to a fall. He did not lose
consciousness. MRI and MRA studies of the brain and neck showed a chronic lacunar
infarct in the right cerebellar hemisphere and a few scattered foci of FLAIR signal in the
periventricular white matter, thought to be sequelae of small vessel ischemic disease. The
risk and benefit of an antiplatelet agent given his history was carefully discussed in the
Benign Hematology group. It was decided that the platelet function defect was not an
absolute contraindication to an anti-platelet agent but that something other than ASA
should be used given that his specific platelet defect was an ASA-like phenotype. The
consensus was to start him on Plavix, which tolerated well with mild bruising. He was
referred to our lab for further characterization of his platelet disorder.
Relevant Past Medical History:
- Coronary artery disease
- Hypertension.
- Possible mitral valve prolapse.
- Heterozygous alpha-thalassemia trait
- Thoracic aneurysm
Family History:
Significant for cerebral hemorrhage in mother at age 81
No known family history of anemia or connective tissue disorders.
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Genetic Test Results:
A heterozygous missense variant of uncertain significance was detected in the PLCβ2
gene:NM_001284298:exon27:c.G3037A:p.E1013K (chr15:40582993). This change is
located at a semi-conserved residue in evolution. It is not seen in the general population.
PLCβ2 is a critical regulator of platelet responses upon activation.
Case Discussion:
This patient consistently showed no aggregatory response to sodium arachidonate
and a weak response to epinephrine on standard clinical tests. We reconfirmed the poor
response to ADP and collagen shown in Table 1 (Figure 7a). The absence of aggregation
upon stimulation by various agonists suggests a defect in a common signaling pathway.
Furthermore, the normal serotonin levels indicate normal dense granule content and
release from platelets. Interestingly, and distinct from what we observed with DM
platelets, the patient’s platelets contained a normal basal cytoplasmic calcium
concentration but a 70% decrease in mitochondrial calcium content (Figure 8a and b).
The rate-limiting step required for intracellular calcium rise is phospholipase C
cleavage of PIP2 to IP3 and DAG. Platelets contain several isoforms of PLC with the
order of expression as follows, PLCϒ2 > PLCβ2 > PLCβ3 > PLCβI > PLC-ϒl > PLCδ1> PLCβ4 (53). Activation of PLCβ isoforms is dependent on agonist binding to a
heterotrimeric G protein coupled receptor. There have been a few studies that have
documented defects in platelet activation due to impaired PLC activity. The characteristic
changes include reduced agonist-induced cytoplasmic rise with intact release using
exogenous IP3 (54). An increase in calcium concentration by several nanomolars is
needed for the action of calcium-sensitive enzymes involved in reorganization of actin
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cytoskeleton and subsequent shape change (55). The inability to mobilize ER calcium
favors bleeding events.
Sustained elevation of cytoplasmic calcium in microdomains drive mitochondrial
calcium uptake. Mitochondrial membranes are closely apposed in regions with the ER
membrane to create this microenvironment. PLCβ2 deficiency results in an inability to
raise threshold cytoplasmic calcium concentration to micromolar levels required for
MCU activity. As such, there is a compensatory overexpression of mitochondrial calcium
channels (Figure 8c).
Although basal apoptosis is similar between the healthy control and patient
sample, PS externalization is decreased by approximately 30 % (Figure 7b). Given the
importance of mitochondrial calcium rise in PS exposure, thrombin activation or H2O2
treatment of PLCβ2-deficient platelets will not yield calcium flux into the mitochondria
required for mPTP opening and PS externalization providing another explanation for the
excessive bleeding observed in these patients.
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Overall Conclusion:
Mitochondrial calcium clearly plays an important role in platelet function and
needs to be tightly regulated. The excess of mitochondrial calcium as observed with DM
platelets may arise from a combination of increased cytosolic calcium, reduced MICU2
and oxidative nitrosylation of MICU1. This contributes to mitochondrial damage,
apoptosis and thrombosis observed in DM platelets. Conversely in our patient, the
reduction of mitochondrial calcium through a PLCβ2 mutation leads to recurrent bleeding
episodes. Thus, mitochondrial function extends beyond being the “cellular battery” in
platelets. They actively coordinate and regulate platelet activation, and calcium handling
is integral to this process. Both too little or too much can lead to damage and dysfunction.

Future Directions:
Mitochondrial calcium regulation is quite complex. Additional experiments to
elucidate the mechanistic details of regulation in DM platelets are needed. Invitro
experiments in Meg-01 cells or normal platelets under hyperglycemia should be done to
attempt to recreate the observations in DM platelets. Electrophysiology studies
examining the effect of nitrosylation of MICU1 on calcium current in constituted
phospholipid bilayer will provide insights on how oxidative stress affects channel
activity. Structural studies of the MCU complex in DM would provide supporting
evidence. Finally, the effects of mitochondrial calcium inhibitors on restoring
homeostasis and platelet function should be investigated in DM platelets.
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Figures:

Figure 1: Alterations in cytosolic and endoplasmic reticulum calcium levels in DM
platelets. A, FACS of 5 µM fluoforte-loaded platelets in DM (red line) and healthy
controls (HC – blue line). B, Quantification of raw fluorescence data of cytosolic calcium
concentration as a fold change relative to HC expressed as mean ± SEM. DM fold change
was 1.526 ± 0.096 (n = 4; p = 0.024). C, Characteristic curve obtained upon addition of 1
µM Thapsigargin (TG) for 30 minutes to deplete ER calcium content. D, Fold change in
calcium plateau after TG normalized to basal levels in DM (2.962 ± 0.1783, n=12) and
HC (3.3 ± 0.2455, n=8) with p = 0.27.
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Figure 2: Mitochondrial Calcium Overload in DM platelets. A, FACS plot of
representative geometric mean fluorescence intensities in 5 µM Rhod2 loaded platelets.
Red curve indicates DM sample and blue for healthy control (HC). B, Fold change in
fluorescence intensity relative to HC (n= 5). DM fold rise was 1.776 ± 0.269 (n=8; p =
0.0466). C, Representative curve of CCCP-induced mitochondrial calcium efflux. The
black curve represents healthy sample and the gray is for DM sample. D, Area under
curve analysis showing total mitochondrial content. DM content was (31.46 ± 1.697,
n=5) versus (15.83 ± 1.179, n=5) in HC with p<0.0001.
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Figure 3: Aberrant mitochondrial function and apoptotic activity in DM platelets.
A, Mitochondrial membrane potential (Δψm) was measured by incubating washed
platelets with 20 nM Mitotracker Deep Red while phosphatidylserine exposure was
detected by 1 µM FITC-Annexin V. B, Graph shows percentage of the Annexin Vpositive platelet population in DM (67.78 ± 9.088 %, n=5) and HC (9.547 ± 2.777 %,
n=3). p = 0.0032. C, Percentage of platelets with poor mitochondrial health (low Δψm).
HC - 7.63 ± 2.627 %, n=4 and DM - 63.73 ± 6.295 %, n=7 with p = 0.0001. D, Apoptotic
population in DM (59.37 ± 2.726 %, n=6) vs. HC (16.46 ± 6.785 %, n=4) with p =
0.0001. E, Ultrastructure of whole platelets showing mitochondrial morphology.
Arrowheads show the areas of disruption in the mitochondrial membrane.
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Figure 4: Correlation of mitochondrial calcium level with the various sub-groups of
DM platelets. The red curve on the FACS plot represents Q1, which is the healthy
platelet fraction; the blue curve is Q2, the activated platelets and the green curve is Q3,
the apoptotic fraction. (n = 5; ANOVA p = 0.0057).
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Figure 5: Expression levels of the protein subunits of mitochondrial calcium
complex. The subunits include HK-1 (hexokinase-1), MCU (mitochondrial calcium
uniporter), VDAC (voltage dependent anion channel), MICU1 (mitochondrial calcium
uptake 1) and MICU2 (mitochondrial calcium uptake 2). Quantification was performed
by densitometry band analysis of proteins normalized to B-actin (the loading control)
with the mean ± SEM shown. P-value for MICU2 change was 0.015. The western blots
were done three times.
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Figure 6: Augmented MICU1-MCU interaction may mediate calcium flux into the
mitochondria. A, Immunoprecipitation of core subunit (MCU) of mitochondrial calcium
complex. Immunoblot bands of associated subunits. B, Immunoprecipitation of MICU1
showing the level of nitrosylation. N = 1.
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Figure 7: Platelet function profile in a patient with a bleeding disorder (PD#2). A,
Platelet aggregation in platelet rich plasma in response to 1 µg/ml collagen or 1 µM ADP
measured as percent light transmission in Chronolog aggregometer. B, Comparison of
apoptotic activity in washed platelets based simultaneous measurement of mitochondrial
membrane potential (Δψm) with 20 nM Mitotracker Deep Red and phosphatidylserine
using 1 µM FITC-Annexin V.
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Figure 8: Calcium stores in bleeding disorder. A, Cytosolic calcium FACS plot in 5
µM Fluoforte-loaded platelets along with the relative change to healthy control (HC). B,
Mitochondrial calcium as shown by the geometric mean fluorescence intensities of 5 µM
Rhod2–loaded platelets with the relative change to HC. Red line is HC and blue is
platelet disorder (PD). C, Mitochondrial calcium complex expression in bleeding
disorder. B-actin served as loading control.
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Supplemental Figure 1: Validation of mitochondrial sequestration of Rhod2. A,
Quenching of cytosolic Rhod2 with 100 µM MnCl2. B, Confocal microscopy showing
distribution of Rhod2 signal after manganese quenching in platelets.
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